Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy

被引：18
作者：
Seifert, Robert [1 ]
Kessel, Katharina [1 ]
Boegemann, Martin [2 ]
Koehler, Michael [3 ]
Roll, Wolfgang [1 ]
Stegger, Lars [1 ]
Weckesser, Matthias [1 ]
Rahbar, Kambiz [1 ]
机构：
[1] Univ Hosp Munster, Dept Nucl Med, Albert Schweitzer Campus 1,Gebaude A1, D-48149 Munster, Germany
[2] Univ Hosp Munster, Dept Urol, Munster, Germany
[3] Univ Hosp Munster, Dept Clin Radiol, Munster, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2020年 / 61卷 / 05期
关键词：
PSMA; prostate cancer; SIRT; LU-177-PSMA-617 RADIOLIGAND THERAPY; SURVIVAL; CHEMOTHERAPY; GUIDELINE;
D O I：
10.2967/jnumed.119.233429
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
The aim of this study was to evaluate the efficacy of Lu-177-prostate-specific membrane antigen (PSMA)-617 (Lu-177-PSMA) and selective internal radiation therapy (SIRT) for the treatment of liver metastases of castration-resistant prostate cancer. Methods: Safety and survival of patients with metastatic castration-resistant prostate cancer and liver metastases assigned to Lu-177-PSMA alone (n = 31) or in combination with SIRT (n = 5) were retrospectively analyzed. Additionally, a subgroup (n = 10) was analyzed using morphologic and molecular response criteria. Results: Median estimated survival was 5.7 mo for Lu-177-PSMA alone and 8.4 mo for combined sequential Lu-177-PSMA and SIRT. Lu-177-PSMA achieved discordant therapy responses with both regressive and progressive liver metastases in the same patient (best vs. worst responding metastases per patient: -35% vs. +63% diameter change; P < 0.05). SIRT was superior to Lu-177-PSMA for the treatment of liver metastases (0% vs. 56% progression). Conclusion: The combination of Lu-177-PSMA and SIRT is efficient and feasible for the treatment of advanced prostate cancer. Lu-177-PSMA alone seems to have limited response rates in the treatment of liver metastases.
引用
收藏
页码：723 / 728
页数：6
相关论文
共 22 条
[11]   Radioembolization for the Treatment of Liver Tumors General Principles [J].
Kennedy, Andrew ;
Coldwell, Douglas ;
Sangro, Bruno ;
Wasan, Harpreet ;
Salem, Riad .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (01) :91-99
[12]   Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617 [J].
Kessel, Katharina ;
Seifert, Robert ;
Schaefers, Michael ;
Weckesser, Matthias ;
Schlack, Katrin ;
Boegemann, Martin ;
Rahbar, Kambiz .
THERANOSTICS, 2019, 9 (17) :4841-4848
[13]   90Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer [J].
Levillain, Hugo ;
Derijckere, Ivan Duran ;
Marin, Gwennaelle ;
Guiot, Thomas ;
Vouche, Michael ;
Reynaert, Nick ;
Hendlisz, Alain ;
Vanderlinden, Bruno ;
Flamen, Patrick .
EJNMMI RESEARCH, 2018, 8
[14]   Development of Carcinoid Tumour in Hormonally Treated Adenocarcinoma of the Prostate [J].
Molenaar, Joery P. F. ;
Baten, Anique ;
Blokx, Willeke A. M. ;
Hoogendam, Arjen .
EUROPEAN UROLOGY, 2009, 56 (05) :874-877
[15]   Liver metastases in prostate carcinoma:: clinical characteristics and outcome [J].
Pouessel, Damien ;
Gallet, Blandine ;
Bibeau, Frederic ;
Avances, Christophe ;
Iborra, Francois ;
Senesse, Pierre ;
Culine, Stephane .
BJU INTERNATIONAL, 2007, 99 (04) :807-811
[16]   PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival [J].
Rahbar, K. ;
Boegemann, M. ;
Yordanova, A. ;
Eveslage, M. ;
Schaefers, M. ;
Essler, M. ;
Ahmadzadehfar, H. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (01) :12-19
[17]   PSMA Theranostics: Current Status and Future Directions [J].
Rahbar, Kambiz ;
Afshar-Oromieh, Ali ;
Jadvar, Hossein ;
Ahmadzadehfar, Hojjat .
MOLECULAR IMAGING, 2018, 17
[18]   Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer [J].
Rahbar, Kambiz ;
Boegeman, Martin ;
Yordanova, Anna ;
Eveslage, Maria ;
Schaefers, Michael ;
Essler, Markus ;
Ahmadzadehfar, Hojjat .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (02) :243-246
[19]   German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients [J].
Rahbar, Kambiz ;
Ahmadzadehfar, Hojjat ;
Kratochwil, Clemens ;
Haberkorn, Uwe ;
Schaefers, Michael ;
Essler, Markus ;
Baum, Richard P. ;
Kulkarni, Harshad R. ;
Schmidt, Matthias ;
Drzezga, Alexander ;
Bartenstein, Peter ;
Pfestroff, Andreas ;
Luster, Markus ;
Luetzen, Ulf ;
Marx, Marlies ;
Prasad, Vikas ;
Brenner, Winfried ;
Heinzel, Alexander ;
Mottaghy, Felix M. ;
Ruf, Juri ;
Meyer, Philipp Tobias ;
Heuschkel, Martin ;
Eveslage, Maria ;
Boegemann, Martin ;
Fendler, Wolfgang Peter ;
Krause, Bernd Joachim .
JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (01) :85-90
[20]   Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer [J].
Rahbar, Kambiz ;
Bode, Axel ;
Weckesser, Matthias ;
Avramovic, Nemanja ;
Claesener, Michael ;
Stegger, Lars ;
Boegemann, Martin .
CLINICAL NUCLEAR MEDICINE, 2016, 41 (07) :522-528
123